先看重点
在48项随机试验共344716名参与者中,药物使收缩压降低5 mm Hg,可降低主要心血管事件的风险(无既往心血管疾病者风险比0.91,有既往心血管疾病者0.89),起始血压为正常或正常高值时同样如此。这些试验发表于1972年至2013年,中位随访4.15年,无法反映长期效果和当代诊疗情况。
证据类型
证据综述
解读依据
公开摘要
阅读重点
方法与适用范围
研究在问什么
对于血压已处于正常或正常高值的人,无论是否已有心血管疾病,药物降压是否有益尚不明确。研究者汇总随机试验的个体参与者数据,观察治疗对主要心血管事件的影响如何随起始收缩压而变化。
研究了谁,如何研究
个体参与者水平数据荟萃分析,纳入48项随机试验,比较降压药与安慰剂或其他类别降压药,或强化与非强化降压方案,每组随访均不少于1000人年。仅针对心力衰竭或急性期短期干预的试验被排除。降压治疗试验者协作组获得了51项发表于1972年至2013年的研究数据。按是否有既往心血管疾病,并在七个收缩压分层(从<120到≥170 mm Hg)中分析疗效。主要结局为主要心血管事件(致死和非致死性卒中、心肌梗死或缺血性心脏病,或导致死亡或住院的心力衰竭),按意向性治疗分析。经费来自英国心脏基金会、英国国家卫生研究院和牛津马丁学院。
主要发现
以下为作者报告的结果。数字须连同人群和不确定性一起阅读。
- 1数据涵盖344716名参与者(157728人有既往心血管疾病,186988人没有)。中位随访4.15年后,42324人(12.3%)至少发生一次主要心血管事件。
- 2收缩压每降低5 mm Hg,无既往心血管疾病者的风险比为0.91(95%置信区间0.89-0.94),有既往心血管疾病者为0.89(95%置信区间0.86-0.92)。
- 3每1000人年发病率:无既往心血管疾病者对照组31.9、干预组25.9;有既往心血管疾病者分别为39.7和36.0。
- 4没有可靠证据表明疗效因基线心血管疾病状态或收缩压分层而不同。治疗前,有既往疾病者中19.8%、无既往疾病者中8.0%的收缩压低于130 mm Hg。
局限与不确定性
- 1试验跨越1972年至2013年,之后的基础治疗和用药情况已有变化。
- 2中位随访仅4.15年,更长期的效果未知。
- 3“获益不随基线血压而变化”来自亚组分析,统计效能低于总体分析。
- 4摘要未报告药物不良反应,而这对血压正常者的治疗尤为重要。本解读仅基于摘要。
对日常健康的启示
该分析支持在试验人群中,无论是否患有心血管疾病,药物降压带来的相对获益相近,作者认为沟通时应强调降低心血管风险本身。是否开始或调整降压药,应由本人与医生共同决定。
如何联系自己的数据
经过验证的上臂式血压计是合适的家用工具:每次在相同时间、坐位休息后测量,看数天到数周的平均值,而不是单次读数。腕戴设备的血压估算不等同于袖带测量值。
如何理解这类证据
先看纳入了哪些设计、检索与偏倚评估如何完成,以及检索截止日期;发表新不代表底层证据都是最新的。
作者的结构化摘要 English
以下英文摘要按记录的开放许可转载,属于作者原始材料,不是 MoveVitals 的解读。上方已提供研究解读,分别说明作者结果与本站解释;重要结论可直接核对原文。
Background
The effects of pharmacological blood pressure lowering at normal or high-normal blood pressure ranges in people with or without pre-existing cardiovascular disease remains uncertain. We analysed individual participant data from randomised trials to investigate the effects of blood pressure lowering treatment on the risk of major cardiovascular events by baseline levels of systolic blood pressure.
Methods
We did a meta-analysis of individual participant-level data from 48 randomised trials of pharmacological blood pressure lowering medications versus placebo or other classes of blood pressure-lowering medications, or between more versus less intensive treatment regimens, which had at least 1000 persons-years of follow-up in each group. Trials exclusively done with participants with heart failure or short-term interventions in participants with acute myocardial infarction or other acute settings were excluded. Data from 51 studies published between 1972 and 2013 were obtained by the Blood Pressure Lowering Treatment Trialists' Collaboration (Oxford University, Oxford, UK). We pooled the data to investigate the stratified effects of blood pressure-lowering treatment in participants with and without prevalent cardiovascular disease (ie, any reports of stroke, myocardial infarction, or ischaemic heart disease before randomisation), overall and across seven systolic blood pressure categories (ranging from <120 to ≥170 mm Hg). The primary outcome was a major cardiovascular event (defined as a composite of fatal and non-fatal stroke, fatal or non-fatal myocardial infarction or ischaemic heart disease, or heart failure causing death or requiring admission to hospital), analysed as per intention to treat.
Findings
Data for 344 716 participants from 48 randomised clinical trials were available for this analysis. Pre-randomisation mean systolic/diastolic blood pressures were 146/84 mm Hg in participants with previous cardiovascular disease (n=157 728) and 157/89 mm Hg in participants without previous cardiovascular disease (n=186 988). There was substantial spread in participants' blood pressure at baseline, with 31 239 (19·8%) of participants with previous cardiovascular disease and 14 928 (8·0%) of individuals without previous cardiovascular disease having a systolic blood pressure of less than 130 mm Hg. The relative effects of blood pressure-lowering treatment were proportional to the intensity of systolic blood pressure reduction. After a median 4·15 years' follow-up (Q1-Q3 2·97-4·96), 42 324 participants (12·3%) had at least one major cardiovascular event. In participants without previous cardiovascular disease at baseline, the incidence rate for developing a major cardiovascular event per 1000 person-years was 31·9 (95% CI 31·3-32·5) in the comparator group and 25·9 (25·4-26·4) in the intervention group. In participants with previous cardiovascular disease at baseline, the corresponding rates were 39·7 (95% CI 39·0-40·5) and 36·0 (95% CI 35·3-36·7), in the comparator and intervention groups, respectively. Hazard ratios (HR) associated with a reduction of systolic blood pressure by 5 mm Hg for a major cardiovascular event were 0·91, 95% CI 0·89-0·94 for partipants without previous cardiovascular disease and 0·89, 0·86-0·92, for those with previous cardiovascular disease. In stratified analyses, there was no reliable evidence of heterogeneity of treatment effects on major cardiovascular events by baseline cardiovascular disease status or systolic blood pressure categories.
Interpretation
In this large-scale analysis of randomised trials, a 5 mm Hg reduction of systolic blood pressure reduced the risk of major cardiovascular events by about 10%, irrespective of previous diagnoses of cardiovascular disease, and even at normal or high-normal blood pressure values. These findings suggest that a fixed degree of pharmacological blood pressure lowering is similarly effective for primary and secondary prevention of major cardiovascular disease, even at blood pressure levels currently not considered for treatment. Physicians communicating the indication for blood pressure lowering treatment to their patients should emphasise its importance on reducing cardiovascular risk rather than focusing on blood pressure reduction itself.
Funding
British Heart Foundation, UK National Institute for Health Research, and Oxford Martin School.
来源与署名
Pharmacological blood pressure lowering for primary and secondary prevention of cardiovascular disease across different levels of blood pressure: an individual participant-level data meta-analysis.
Blood Pressure Lowering Treatment Trialists' Collaboration.
Lancet (London, England) · 2021-05-01
DOI: 10.1016/s0140-6736(21)00590-0 ↗PubMed · 33933205 ↗Europe PMC · 记录的开放许可: cc by ↗摘要版权归原作者,依据来源记录的开放许可转载。中文译文辅助阅读,英文摘要用于核对术语与具体数值;本站的方法学解释与作者结论分别呈现。
MoveVitals 编辑解读 · 健康教育内容 · 未记录个人临床审阅
来源核验日期 2026-11-01
实用健康指南
放在一起读
昼夜活动节律紊乱与更高的死亡风险相关(109,365人)
在7项观察性研究、共109,365名参与者中,昼夜活动对比较弱(相对振幅较低)与更高的心血管死亡风险(风险比[HR]1.50,95%置信区间1.13至1.98)和全因死亡风险(HR 1.46,95%置信区间1.27至1.68)相关。证据基础小,又是观察性的,不能说明改善节律就能降低风险,疾病本身也可能扰乱节律。
Journal of the American Heart Association
五类运动都降低了静息血压,等长训练降幅最大
汇总270项随机试验、共15,827名参与者的结果,有氧、抗阻、联合、间歇和等长训练与无干预对照组相比都降低了静息血压(各P<0.001),其中等长训练降幅最大:收缩压下降8.24 mm Hg,舒张压下降4.00 mm Hg。各方式之间的排序部分来自间接比较,各试验也不尽相同,所以排序不是个人的运动处方。
British Journal of Sports Medicine
盐替代品使中国农村高危人群的卒中、主要心血管事件和死亡率下降
在中国农村600个村庄、20,995名有卒中史或年龄在60岁及以上且有高血压的人中,使用盐替代品(氯化钠75%、氯化钾25%)的卒中发生率低于普通盐:平均随访4.74年,每1000人年29.14次对33.65次(率比0.86,95%置信区间0.77至0.96;P=0.006)。死亡也更低(率比0.88),严重高钾血症事件没有显著增多,但试验为开放标签设计,且在中国农村开展。
The New England Journal of Medicine
智能手表脉搏不规则提醒较少见,做贴片检查者34%确有房颤
在419,297名没有已知心房颤动(房颤)的苹果手表用户中,0.52%收到脉搏不规则提醒;返还可用心电贴片的450人中,34%确认有房颤(97.5%置信区间29至39)。提醒发出时恰有贴片记录的,通知的阳性预测值为0.84(95%置信区间0.76至0.92),但收到提醒者中仅20.8%返还了贴片,没有收到提醒的人未被监测,所以手表没有提醒并不能排除房颤。
The New England Journal of Medicine

